IRIS
LODOLA, Alessio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.118
AS - Asia 7.223
EU - Europa 5.991
SA - Sud America 1.041
AF - Africa 424
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 4
Totale 22.807
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.863
SG - Singapore 2.535
CN - Cina 1.938
IT - Italia 1.596
VN - Vietnam 1.170
IE - Irlanda 826
FI - Finlandia 822
BR - Brasile 808
SE - Svezia 663
DE - Germania 648
HK - Hong Kong 501
FR - Francia 287
ZA - Sudafrica 277
UA - Ucraina 243
BD - Bangladesh 225
NL - Olanda 204
TR - Turchia 202
IN - India 184
GB - Regno Unito 180
CA - Canada 156
RU - Federazione Russa 122
AT - Austria 93
AR - Argentina 82
CI - Costa d'Avorio 70
BE - Belgio 62
ID - Indonesia 61
JP - Giappone 60
MX - Messico 59
PL - Polonia 48
ES - Italia 47
IQ - Iraq 43
KR - Corea 41
PK - Pakistan 38
TH - Thailandia 38
CZ - Repubblica Ceca 37
VE - Venezuela 35
EC - Ecuador 31
PH - Filippine 31
JO - Giordania 26
LT - Lituania 22
CO - Colombia 20
MA - Marocco 20
SA - Arabia Saudita 20
PY - Paraguay 17
UZ - Uzbekistan 16
CL - Cile 15
RO - Romania 14
TW - Taiwan 14
KE - Kenya 13
BO - Bolivia 11
HU - Ungheria 11
MY - Malesia 11
PE - Perù 11
HR - Croazia 10
TN - Tunisia 10
EG - Egitto 9
UY - Uruguay 9
IL - Israele 8
JM - Giamaica 8
AL - Albania 7
ET - Etiopia 7
MD - Moldavia 7
PS - Palestinian Territory 7
AZ - Azerbaigian 6
CR - Costa Rica 6
DZ - Algeria 6
KZ - Kazakistan 6
RS - Serbia 6
SN - Senegal 6
CH - Svizzera 5
DO - Repubblica Dominicana 5
HN - Honduras 5
KG - Kirghizistan 5
LB - Libano 5
NP - Nepal 5
TT - Trinidad e Tobago 5
BG - Bulgaria 4
EU - Europa 4
IR - Iran 4
LV - Lettonia 4
NO - Norvegia 4
OM - Oman 4
AE - Emirati Arabi Uniti 3
BY - Bielorussia 3
DK - Danimarca 3
GT - Guatemala 3
SI - Slovenia 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
AO - Angola 2
AU - Australia 2
CY - Cipro 2
GE - Georgia 2
GR - Grecia 2
NI - Nicaragua 2
PA - Panama 2
TJ - Tagikistan 2
A1 - Anonimo 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
Totale 22.784
Salva come PNG Salva come JPEG
Città #
Singapore 1.259
Ashburn 948
Dublin 820
San Jose 755
Chandler 742
Dallas 576
Parma 535
Santa Clara 494
Hong Kong 470
Beijing 453
Ann Arbor 398
Ho Chi Minh City 366
Jacksonville 295
Boardman 292
Johannesburg 263
Hanoi 257
Dearborn 246
Munich 243
Los Angeles 209
New York 208
Nanjing 167
Izmir 161
Shanghai 161
Helsinki 153
Lauterbourg 147
Princeton 136
Hefei 129
Wilmington 112
Milan 106
Bremen 79
São Paulo 78
San Mateo 77
Columbus 72
Abidjan 70
Vienna 70
Bologna 69
Shenyang 69
Toronto 67
Council Bluffs 65
Buffalo 62
Haiphong 57
Brussels 54
Moscow 54
Tokyo 51
Kunming 49
London 48
Jinan 47
Seattle 45
Hebei 44
Da Nang 42
Frankfurt am Main 42
Nanchang 42
Turku 42
Jakarta 41
Modena 41
The Dalles 41
Düsseldorf 40
Guangzhou 40
Des Moines 37
Montreal 36
Changsha 35
Dong Ket 34
Seoul 34
Brescia 33
Chicago 32
Jiaxing 32
Orem 32
Warsaw 32
Rio de Janeiro 30
Woodbridge 30
Tianjin 29
Nuremberg 28
Bangalore 27
Fremont 27
Rome 27
Stockholm 27
Houston 26
San Francisco 25
Brooklyn 24
Denver 24
Mexico City 24
Ankara 23
Chennai 23
Naples 23
Phoenix 23
Pune 23
Amman 21
Bangkok 21
Hangzhou 21
Atlanta 20
Brno 20
Belo Horizonte 19
Lubbock 19
Manchester 19
Ottawa 19
Dhaka 18
Norwalk 18
Zhengzhou 18
Biên Hòa 17
Curitiba 17
Totale 13.766
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 350
A Pharmacological Investigation of Eph-Ephrin Antagonism in Prostate Cancer: UniPR1331 Efficacy Evidence 300
Benzisothiazolinone Derivatives as Potent Allosteric Monoacylglycerol Lipase Inhibitors That Functionally Mimic Sulfenylation of Regulatory Cysteines 278
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 264
Targeting the Eph/ephrin system as anti-inflammatory strategy in IBD 253
Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line 251
Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach 251
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 244
Inhibition of Eph/ephrin interaction with the small molecule UniPR500 improves glucose tolerance in healthy and insulin-resistant mice 243
Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction 223
Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice 219
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 219
Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties 218
Development of an orally bioavailable small molecule targeting Eph-ephrin system: in vitro and in vivo anticancer activity. 217
A critical cysteine residue in monoacylglycerol lipase is targeted by a new class of isothiazolinone-based enzyme inhibitors. 217
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 215
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 214
Metabolic Soft Spot and Pharmacokinetics: Functionalization of C-3 Position of an Eph–Ephrin Antagonist Featuring a Bile Acid Core as an Effective Strategy to Obtain Oral Bioavailability in Mice 210
Dibasic biphenyl H(3) receptor antagonists: Steric tolerance for a lipophilic side chain. 208
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 208
N-Acylethanolamine Acid Amidase (NAAA): Structure, Function, and Inhibition 207
5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity 206
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 203
Discovery and development of Eph-ephrin antagonists endowed with antiangiogenic properties 202
Amino acid derivatives as palmitoylethanolamide prodrugs: Synthesis, in vitro metabolism and in vivo plasma profile in rats 201
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 198
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 197
Application of 3D-QSAR in the Rational Design of Receptor Ligands and Enzyme Inhibitors 194
A catalytic mechanism for cysteine N-terminal nucleophile hydrolases, as revealed by free energy simulations 194
Free-Energy Simulations Support a Lipophilic Binding Route for Melatonin Receptors 191
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 191
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability 189
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 185
NEW EPH ANTAGONISTS DISCRIMINATING BETWEEN EPH-AS AND EPH-BS CLASSES 177
Atropisomerism and Conformational Equilibria: Impact on PI3Kδ Inhibition of 2-((6-Amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one (IC87114) and Its Conformationally Restricted Analogs 176
Structure–Activity Relationships and Mechanism of Action of Eph–ephrin Antagonists: Interaction of Cholanic Acid with the EphA2 Receptor 176
N-Acylethanolamine Acid Amidase (NAAA): Mechanism of Palmitoylethanolamide Hydrolysis Revealed by Mechanistic Simulations 176
Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation 174
inibitori eph-ephrin biodisponibili oralmente 171
270 Discovery, development and optimization of low molecular weight EPH–ephrin protein–protein inhibitors 168
UniPR1331: small Eph/ephrin antagonist beneficial in intestinal inflammation by interfering with type-B signaling 165
JAK3 Inhibitors: Covalent and Noncovalent Interactions of a Cyanamide Group Investigated by Multiscale Free-Energy Simulations 163
Discovery and development of small molecules targeting Eph-ephrin system in glioblastoma: an academic history 163
Development of 3-oxo-cholenic derivatives as Eph antagonists able to block in vitro angiogenesis 163
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 161
Protein-Protein Interaction Inhibitors Targeting the Eph-Ephrin System with a Focus on Amino Acid Conjugates of Bile Acids 161
Eph/ephrin targeting with a small molecule improves glucose tolerance in healthy and insulin-resistant mice 159
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 158
Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis 156
Cyclohexylcarbamic Acid 3'- or 4'-Substituted Biphenyl-3-yl Esters of as Fatty Acid Amide Hydrolase Inhibitors: Synthesis, Quantitative Structure-Activity Relationships and Molecular Modelling Studies 154
Application of a SCC-DFTB QM/MM approach to the investigation of the catalytic mechanism of fatty acid amide hydrolase. 153
Molecular Determinants of EphA2 and EphB2 Antagonism Enable the Design of Ligands with Improved Selectivity 151
Analysis of adam12-mediated ephrin-a1 cleavage and its biological functions 151
Tetrahydroquinoline Ring as a Versatile Bioisostere of Tetralin for Melatonin Receptor Ligands 151
Evaluation of the anti-tumor activity of small molecules targeting eph/ephrins in apcmin j mice 151
Design and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands. 150
Structure activity relationship of new EphA2 ligands 150
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system 150
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 149
PHARMACOLOGICAL CHARACTERIZATION OF NEW COMPOUNDS AIMED AT INHIBITING EPH-EPHRIN INTERACTION IN GLIOBLASTOMA 148
Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return 148
QM/MM modelling of oleamide hydrolysis in fatty acid amide hydrolase (FAAH) reveals a new mechanism of nucleophile activation 148
Combining pharmacology, target hopping and computational medicinal chemistry to discover novel scaffold targeting EPH-ephrin interaction. 148
Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists 147
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 147
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 146
N-(2-Oxo-3-oxetanyl)carbamic Acid Esters as N-Acylethanolamine Acid Amidase Inhibitors: Synthesis, Structure–Activity and Structure–Property Relationships. 146
APPLICATION OF COMPUTATIONAL METHODSTO THE DESIGN OF FATTY ACID AMIDE HYDROLASE(FAAH) INHIBITORS BASED ON A CARBAMICTEMPLATE STRUCTURE 145
Discovery and development of low molecular weight Eph-ephrin protein-protein inhbi-tors endowed with antiangiogenic activity 145
L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib 143
The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells 141
Design and SAR Analysis of Covalent Inhibitors Driven by Hybrid QM/MM Simulations 141
Aromatic interactions and rotational strengths within protein environment: An electronic structural study on beta-lactamases from class A 140
UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice 140
Applications and Advances of QM/MM methods in Computational Enzymology 139
Target-hopping: a useful approach to identify novel Eph receptor antagonists 139
Metadynamics for perspective drug design: Computationally driven synthesis of new protein-protein interaction inhibitors targeting the EphA2 receptor 138
Target Hopping as a Useful Tool for the Identification of Novel EphA2 Protein–Protein Antagonists 136
Identification of bivalent ligands with melatonin receptor agonist and fatty acid amide hydrolase (FAAH) inhibitory activity that exhibit ocular hypotensive effect in the rabbit 136
MT2 selective melatonin receptor antagonists: design and structure-activity relationships 135
Cholenic acid derivative UniPR1331 impairs tumor angiogenesis via blockade of VEGF/VEGFR2 in addition to Eph/ephrin 134
Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors 134
Eph-ephrin antagonism in tumor angiogenesis and growth: UniPR1331 preclinical evidence. 134
N-tert-butyloxycarbonyl-Phe-Leu-Phe-Leu-Phe (BOC2) inhibits the angiogenic activity of heparin-binding growth factors. 133
Free-energy studies reveal a possible mechanism for oxidation-dependent inhibition of MGL 133
Metadynamics Simulations Distinguish Short- and Long-Residence-Time Inhibitors of Cyclin-Dependent Kinase 8. 133
Different roles for the acyl chain and the amine leaving group in the substrate selectivity of N-Acylethanolamine acid amidase 133
Spirotetrahydroisoquinoline-Based Histone Deacetylase Inhibitors as New Antifibrotic Agents: Biological Evaluation in Human Fibroblasts from Bronchoalveolar Lavages of Idiopathic Pulmonary Fibrosis Patients 132
Role of sphingolipid metabolism in osimertinib-resistance in EGFR-mutated NSCLC models 132
Mechanistic Modeling of Monoglyceride Lipase Covalent Modification Elucidates the Role of Leaving Group Expulsion and Discriminates Inhibitors with High and Low Potency 132
A catalytically silent FAAH-1 variant drives anandamide transport in neurons 132
Highly Potent and Selective MT2 Melatonin Receptor Full Agonists from Conformational Analysis of 1-Benzyl-2-acylaminomethyl-tetrahydroquinolines 132
In silico drug discovery of melatonin receptor ligands with therapeutic potential 131
Synthesis, Enantiomeric Resolution, and Structure-Activity Relationship Study of a Series of 10,11-Dihydro-5H-Dibenzo[a,d]cycloheptene MT(2) Receptor Antagonists. 131
Predicting the reactivity of nitrile-carrying compounds with cysteine: a combined computational and experimental study. 131
Irreversible EGFR inhibitor compounds with antiproliferative activity 130
Pushing the Boundaries of Vinylogous Reactivity: Catalytic Enantioselective Mukaiyama Aldol Reactions of Highly Unsaturated 2-Silyloxyindoles 130
Unbinding Kinetics of Muscarinic M3 Receptor Antagonists Explained by Metadynamics Simulations 128
Lithocholic acid competitively inhibitis EphA2-ephrinA1 binding: pharmacological and structural considerations. 127
Are we using the right pharmacological tools to target EphA4? 127
Totale 17.162
Salva come PNG Salva come JPEG
Categoria #
all - tutte 77.028
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 77.028
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202182 0 0 0 0 0 0 0 0 0 0 0 82
2021/2022850 30 24 24 86 58 28 109 100 58 67 35 231
2022/20233.112 314 309 172 240 288 358 41 196 983 45 127 39
2023/20241.256 82 72 42 43 89 270 118 111 46 64 142 177
2024/20254.391 137 217 271 250 455 481 273 263 563 399 382 700
2025/20269.215 796 966 1.110 823 1.200 490 978 310 1.127 725 413 277
Totale 23.147